SYD 0073
Latest Information Update: 12 Sep 2023
Price :
$50 *
At a glance
- Originator Synovo
- Class Macrolides
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Chronic obstructive pulmonary disease; Cystic fibrosis
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 12 Sep 2023 Preclinical development of SYD 0073 for Cystic fibrosis and Chronic obstructive pulmonary disease is ongoing in Germany (Synovo pipeline, September 2023)
- 12 Sep 2023 SYD 0073 is available for licensing as of 12 Sep 2023. https://synovo.com/innovation/#chroniclungconditions
- 26 Jul 2016 Preclinical trials in Chronic obstructive pulmonary disease in Germany (unspecified route)